Rubraca (Rucaparib)

Rubraca (rucaparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:

• Ovarian cancer: for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
• Prostate cancer: for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy.

Note: The indication of prostate cancer is approved under accelerated approval based on objective response rate (RR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Recommended Dosage:
The recommended dosage of Rubraca is 600 mg (two 300 mg tablets) taken orally twice daily with or without food, for a total daily dose of 1,200 mg. Continue treatment until there is evidence of disease progression or unacceptable toxicity.
If a patient misses a dose of this therapeutic drug, instruct the patient to take the very next dose at its scheduled time. Vomited doses must not be replaced.
Patients receiving treatment with Rubraca for mCRPC should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.

• Treatment with Rucaparib has been associated with rare but serious cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Monitor patients regularly with blood tests. Discontinue treatment if prolonged hematologic toxicity is observed and further evaluation confirms MDS or AML development.
• Animal studies suggest Rucaparib has potential reproductive toxic effects, therefore, pregnant women should avoid taking the medication. Women considering pregnancy are advised to use effective contraception during treatment and for six months after the last dose.
• It is unknown if Rucaparib passes into breast milk, but due to potential risks to the infant, breastfeeding is not recommended during treatment and for two weeks after the last dose. Counsel mothers to avoid nursing to prevent possible serious adverse effects.
• The safety and effectiveness of Rucaparib in pediatric patients have not been established. Children and adolescents should not take this medication unless part of a clinical study. No dosage or usage recommendations are currently available for patients under 18 years of age.
• Most patients with mild to moderate renal impairment can be given standard doses without any alterations. However, there is scant information available concerning those with severe renal impairment. These patients should be observed closely for possible toxic effects, and if signs of toxicity become evident, careful dose modifications or withdrawal of treatment should be made.
• Patients with mild hepatic impairment do not require any changes to their dosage. However, people with moderate to severe liver impairment should be more cautious due to a lack of information. Throughout the course of treatment, monitor liver function and modify drug therapy in cases where there is considerable harm.

What documents are required to import RUBRACA to India?

RUBRACA (rucaparib) tablets can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is RUBRACA available in India?

RUBRACA (rucaparib tablets) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On availability of Rubraca in India (Mumbai, Kolkata,
• Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar,
• Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

RUBRACA can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of RUBRACA (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Rubraca 200 mg/250 mg/300 mg Tablet price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source RUBRACA (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

What is the Generic Name for the trade name drug Rubraca®?

Rucaparib is the Generic Name for the trade name drug Rubraca®.

What is the Manufacturer's Name of Rubraca®?

Rubraca® is manufactured by Pharma & GmbH.

What is the dosage and form of Rubraca® supplied?

Rubraca is supplied in Tablets: 200 mg, 250 mg, and 300 mg for oral administration.

What are the most common side effects of Rubraca® 200 mg/250 mg/300 mg tablets?

The most common side effects of Rubraca® in patients with ovarian cancer are nausea, anemia, fatigue (including asthenia), AST/ALT increased, dizziness, vomiting, decreased appetite, dyspnea, diarrhea, thrombocytopenia, dysgeusia, neutropenia, blood creatinine increased, dyspepsia, photosensitivity reaction, and leukopenia. Side effects in patients with BRCAmutated mCRPC are fatigue (including asthenia), rash, nausea, anemia, ALT/AST increased, decreased appetite, vomiting, constipation, thrombocytopenia, and diarrhea.

How much does Rubraca® 200 mg/250 mg/300 mg Tablet cost in India?

Prices of Rubraca tablets may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Rubraca 200 mg/250 mg/300 mg cost in India, please call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Rubraca® 200 mg/250 mg/300 mg Tablets be available in SAARC countries?

Apart from Gulf countries, Rubraca® can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Rubraca® tablets in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Rubraca® 200 mg/250 mg/300 mg tablets online in India?

Yes, one can buy Rubraca 200 mg/250 mg/300 mg online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the legal supply of Rubraca® tablets through legal channels.

What are the storage conditions of Rubraca® 200 mg/250 mg/300 mg Tablets?

Store Rucaparib oral tablets at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).